Contact: Cassandra Aviles
Massachusetts General Hospital
Caption: Ascites fluid from ovarian cancer patients is introduced through a filter into an inlet (left) where magnetically labeled benign cells are trapped. The remaining fluid passes through a microchip containing microwells where antibody-labeled tumor cells are captured (inset) for collection, imaging, and additional analyses.
Credit: Hakho Lee, PhD, and Jaehoon Chung, PhD, MGH Center for Systems Biology
Usage Restrictions: None
Related news release: Clinical waste may prove valuable for monitoring treatment response in ovarian cancer